論文 - 盛武 浩
-
Moritake H., Tanaka S., Nakayama H., Miyamura T., Iwamoto S., Shimada A., Terui K., Saito A., Shiba N., Hayashi Y., Tomizawa D., Taga T., Goto H., Hasegawa D., Horibe K., Mizutani S., Adachi S.
Pediatric Blood and Cancer 64 ( 10 ) 2017年
記述言語：英語 掲載種別：研究論文（学術雑誌）
-
小児急性リンパ性白血病の very late relapse 例の予後 ―九州・山口小児がん治療研究グループ(KYCCSG)ALL 96/02 研究― 査読あり
野口磨依子,稲垣二郎,,岡本康裕,古賀友紀,大園秀一,新小田雄一,中山秀樹, 盛武 浩,堀田紀子,糸長伸能,野村優子,下之段秀美,市村卓也,日高靖文,河野嘉文
日本小児血液・がん学会雑誌 54 ( 5 ) 1046 - 1052 2017年
記述言語：日本語 掲載種別：研究論文（学術雑誌）
-
Clinical and histological findings of autosomal dominant renal-limited disease with LMX1B mutation 査読あり
Konomoto T., Imamura H., Orita M., Tanaka E., Moritake H., Sato Y., Fujimoto S., Harita Y., Hisano S., Yoshiura K., Nunoi H.
Nephrology 21 ( 9 ) 765 - 773 2016年9月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Nephrology
© 2015 Asian Pacific Society of Nephrology Aim: Mutations of LMX1B cause nail-patella syndrome, a rare autosomal dominant disorder. Recently, LMX1B R246Q heterozygous mutations were recognised in nephropathy without extrarenal manifestation. The aim of this study was to clarify characteristics of nephropathy caused by R246Q mutation. Methods: Whole exome sequencing was performed on a large family with nonsyndromic autosomal dominant nephropathy without extrarenal manifestation. Clinical and histological findings of patients with LMX1B mutation were investigated. Results: LMX1B R246Q heterozygous mutation was identified in five patients over three generations. Proteinuria or haematoproteinuria was recognized by urinary screening from all patients in childhood. Proteinuria gradually increased to nephrotic levels and renal function decreased in adolescence. Two patients progressed to end-stage renal disease in adulthood. Renal histology demonstrated minimal change in childhood and focal segmental glomerulosclerosis in adulthood. Using electron microscopy, focal collagen deposition could be detected in glomeruli even when a “moth-eaten appearance” was not apparent in the glomerular basement membrane. In addition, podocin expression in glomerular podocytes was significantly decreased, even in the early stages of disease progression. Conclusion: Comprehensive genetic analyses and collagen or tannic acid staining may be useful for diagnosis of LMX1B-associated nephropathy. While renal prognosis of R246Q may be worse than that of typical NPS nephropathy, signs of podocytopathy can be detected during the infantile period; thus, childhood urinary screening may facilitate early detection.
DOI： 10.1111/nep.12666
-
Noguchi M., Moritake H., Kamimura S., Sonoda M., Ishimura M., Inagaki J.
Bone Marrow Transplantation 53 ( 9 ) 1214 - 1217 2016年9月
記述言語：英語 掲載種別：研究論文（学術雑誌）
-
Yamada A., Moritake H., Kinoshita M., Sawa D., Kamimura S., Iwamoto S., Yamashita Y., Inagaki J., Takahashi T., Shimada A., Obara M., Nunoi H.
Pediatrics International 58 ( 9 ) 905 - 908 2016年9月
記述言語：英語 掲載種別：研究論文（学術雑誌）
-
Relapsed childhood acute myeloid leukemia patient with inversion of chromosome 16 harboring a low FLT3 internal tandem duplication allelic burden and KIT mutations 査読あり
Yamada A, Moritake H, Kinoshita M, Sawa, D, Kamimura S, Iwamoto S, Yamashita Y, Inagaki J, Takahashi T, Shimada A, Obara, M, Nunoi H
Pediatr Int 58 ( 9 ) 905 - 908 2016年9月
掲載種別：研究論文（学術雑誌）
-
High event-free survival rate with minimum-dose-anthracycline treatment in childhood acute promyelocytic leukaemia: a nationwide prospective study by the Japanese Paediatric Leukaemia/Lymphoma Study Group 査読あり
Takahashi H.*, Watanabe T., Kinoshita A., Yuza Y., Moritake H., Terui K., Iwamoto S., Nakayama H., Shimada A., Kudo K., Taki T., Yabe M., Matsushita H., Yamashita Y., Koike K., Ogawa A., Kosaka Y., Tomizawa D., Taga T., Saito AM., Horibe K., Nakahata T., Miyachi H., Tawa A., Adachi S.
Br. J. Haematol. 2016年4月
記述言語：英語 掲載種別：研究論文（学術雑誌）
-
Autoimmunity including intestinal Behçet's disease bearing the KRAS mutation in lymphocytes 査読あり
Moritake H, Takagi M, Kinoshita M, Ohara O, Yamamoto S, Moriguchi S, Nunoi H
Pediatrics 137 ( 3 ) e20152891 2016年3月
担当区分：筆頭著者 掲載種別：研究論文（学術雑誌）
-
Autoimmunity Including Intestinal Behcet Disease Bearing the KRAS Mutation in Lymphocytes: A Case Report. 査読あり
Moritake H, Takagi M, Kinoshita M, Ohara O, Yamamoto S, Moriguchi S, Nunoi H.
Pediatrics 2016年3月
記述言語：英語 掲載種別：研究論文（学術雑誌）
-
Taga T., Watanabe T., Tomizawa D., Kudo K., Terui K., Moritake H., Kinoshita A., Iwamoto S., Nakayama H., Takahashi H., Shimada A., Taki T., Toki T., Ito E., Goto H., Koh K., Saito A., Horibe K., Nakahata T., Tawa A., Adachi S.
Pediatric Blood and Cancer 63 ( 2 ) 248 - 254 2016年2月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Pediatric Blood and Cancer
© 2015 Wiley Periodicals, Inc. Background: On the basis of results of previous Japanese trials for myeloid leukemia in Down syndrome (ML-DS), the efficacy of risk-oriented therapy was evaluated in the Japanese Pediatric Leukemia/Lymphoma Study Group AML-D05 study. Procedure: All patients received induction chemotherapy that consisted of pirarubicin, intermediate-dose cytarabine, and etoposide. Patients who achieved complete remission (CR) after initial induction therapy were stratified to the standard risk (SR) group and received four courses of reduced-dose intensification therapy. Patients who did not achieve CR were stratified to the high risk (HR) group and received intensified therapy that consisted of continuous or high-dose cytarabine. Results: A total of 72 patients were eligible and evaluated. One patient died of sepsis during initial induction therapy. Sixty-nine patients were stratified to SR and two patients to HR. No therapy-related deaths were observed during intensification therapy. The 3-year event-free and overall survival rates were 83.3% ± 4.4% and 87.5% ± 3.9 %, respectively. Age at diagnosis less than 2 years was a significant favorable prognostic factor for risk of relapse (P = 0.009). Conclusions: The attempt of risk-oriented prospective study for ML-DS was unsuccessful, but despite the dose reduction of chemotherapeutic agents, the overall outcome was good, and further dose reduction might be possible for specific subgroups.
DOI： 10.1002/pbc.25789
-
Okamoto Y., Koga Y., Inagaki J., Ozono S., Ueda K., Shimoura M., Itonaga N., Shinkoda Y., Moritake H., Nomura Y., Nakayama H., Hotta N., Hidaka Y., Shimonodan H., Suga N., Tanabe T., Nakashima K., Fukano R., Kawano Y.
International Journal of Hematology 103 ( 2 ) 202 - 209 2016年2月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：International Journal of Hematology
© 2015, The Japanese Society of Hematology. In a previous study of childhood acute lymphoblastic leukemia (ALL) by the Kyushu–Yamaguchi Children’s Cancer Study Group, ALL-96, we achieved a 72.1 % 5-year event-free survival (EFS) and an 84.8 % 5-year overall survival (OS). In a subsequent study, ALL-02, we adopted a vincristine dexamethasone (VCR/DEX) pulse regimen as maintenance therapy in the context of the ALL-96 study using the same risk classification and treatment schedule. A total of 156 pediatric cases of ALL were treated with ALL-02. All of the patients were classified as standard-risk or high-risk. Risk stratification was based on white cell counts, immunophenotype, the presence of central nervous system (CNS) disease at diagnosis, organomegaly, and early treatment response (day 14 bone marrow status). The 7-year EFS and OS rates were 77.7 % (95 % CI 70.6–84.8 %) and 89.5 % (95 % CI 84.6–94.4 %), respectively. CNS 3 status [hazard ratio ( HR) = 5.0, p = 0.009] and high white blood cell count at diagnosis (HR = 2.6, p = 0.047) were risk factors for poor EFS in multivariate analysis. Our strategies to categorize patients into two risk groups, and to treat with a VCR/DEX pulse were feasible and reasonably effective treatments for pediatric ALL.
-
Sporadic paraganglioma caused by de novo SDHB mutations in a 6-year-old girl 査読あり
Imamura H., Muroya K., Tanaka E., Konomoto T., Moritake H., Sato T., Kimura N., Takekoshi K., Nunoi H.
European Journal of Pediatrics 175 ( 1 ) 137 - 141 2016年1月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：European Journal of Pediatrics
© 2015, Springer-Verlag Berlin Heidelberg. Germline mutations in the succinate dehydrogenase complex subunit B (SDHB) gene (SDHB) cause susceptibility to paragangliomas and pheochromocytomas; however, it is exceedingly rare in childhood and especially in sporadic cases. We report the first Japanese pediatric case of paraganglioma with a de novo mutation in the SDHB gene. A 6-year-old girl with convulsions and hypertension was found to have a paravertebral abdominal tumor. Urinary and blood examinations revealed markedly elevated levels of norepinephrine. Following treatment for hypertension, the tumor was removed completely and histological findings were consistent with paraganglioma. Immunohistochemistry studies demonstrated the absence of SDHB protein expression, indicating an underlying SDH mutation with high probability. Germline mutation analysis of the SDHB gene revealed a heterozygous splice site mutation in intron 4 (C.423 + 1G > A). Subsequently, a second somatic genetic change was confirmed by multiplex ligation-dependent probe amplification (MLPA) analysis, showing that deletion of the wild-type allele resulted in loss of function of SDHB. No germline mutations in SDHB were detected in her parents. Conclusion: Genetic testing should be considered for pediatric patients with paragangliomas, even in the absence of familial history, as closer lifelong screening to detect the development of malignancy will be required for patients with SDHB mutations.What is Known• Most sporadic cases of paraganglioma with SDHB mutations occur between adolescence and adulthood.• Screening methods for carriers of SDHB mutations assessing recurrence and detecting developing metastases are yet to be standardized.What is New• The current case of an extra-adrenal paraganglioma with a de novo SDHB mutation had an onset at 6 years.• We suggest much closer periodical observation for these high-risk children.
-
Boron neutron capture therapy (BNCT) as a new approach for clear cell sarcoma (CCS) treatment: Trial using a lung metastasis model of CCS. 査読あり
Andoh T, Fujimoto T, Suzuki M, Sudo T, Sakurai Y, Tanaka H, Fujita I, Fukase N,?Moritake H, Sugimoto T, Sakuma T, Sasai H, Kawamoto T, Kirihata M, Fukumori Y, Akisue T, Ono K, Ichikawa H.
Appl Radiat Isot 2015年12月
記述言語：英語 掲載種別：研究論文（学術雑誌）
-
Paroxysmal nocturnal hemoglobinuria and telomere length predicts response to immunosuppressive therapy in pediatric aplastic anemia. 査読あり
Narita A, Muramatsu H, Sekiya Y, Okuno Y, Sakaguchi H, Nishio N, Yoshida N, Wang X, Xu Y, Kawashima N, Doisaki S, Hama A, Takahashi Y, Kudo K,?Moritake H, Kobayashi M, Kobayashi R, Ito E, Yabe H, Ohga S, Ohara A, Kojima S
Haematologica 2015年12月
記述言語：英語 掲載種別：研究論文（学術雑誌）
-
Potential of boron neutron capture therapy (BNCT) for malignant peripheral nerve sheath tumors (MPNST). 査読あり
Fujimoto T, Andoh T, Sudo T, Fujita I, Fukase N, Takeuchi T, Sonobe H, Inoue M, Hirose T, Sakuma T,?Moritake H, Sugimoto T, Kawamoto T, Fukumori Y, Yamamoto S, Atagi S, Sakurai Y, Kurosaka M, Ono K, Ichikawa H, Suzuki M.
Appl Radiat Isot 2015年12月
記述言語：英語 掲載種別：研究論文（学術雑誌）
-
Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation. 査読あり
Inagaki J,?Moritake H, Nishikawa T, Hyakuna N, Okada M, Suenobu S, Nagai K, Honda Y, Shimomura M, Fukano R, Noguchi M, Kurauchi K, Tanioka S, Okamura J.
Biol Blood Marrow Transplant 2015年11月
記述言語：英語 掲載種別：研究論文（学術雑誌）
-
Outcome of adolescent patients with acute myeloid leukemia treated with pediatric protocols 査読あり
Tomizawa D., Watanabe T., Hanada R., Horibe K., Horikoshi Y., Iwamoto S., Kinoshita A., Moritake H., Nakayama H., Shimada A., Taga T., Takahashi H., Tawa A., Terui K., Hori H., Kawano Y., Kikuta A., Manabe A., Adachi S.
International Journal of Hematology 102 ( 3 ) 318 - 326 2015年9月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：International Journal of Hematology
© 2015, The Japanese Society of Hematology. As past studies of adolescent and young adults (AYA) with acute myeloid leukemia (AML) reported conflicting results, we conducted a retrospective analysis using data from three Japanese pediatric AML studies. Among the 782 patients with de novo AML, 44 were classified as AYA (age ≥15 years at diagnosis), 164 as infants (0–1 year), 413 as younger children (2–11 years), and 161 as older children (12–14 years). While the 5-year event-free survival rate of AYA was not different among the groups, the five-year survival rate (54.7 %) was significantly lower than that of the other three groups (P = 0.019): 68.7 % for infants, 73.2 % for younger children, and 75.5 % for older children. No difference in the 5-year cumulative incidence of relapse was observed, but treatment-related death (TRD) of AYA was significantly higher (29.4 %) than that in infants (14.8 %), younger children (10.2 %), and older children (13.8 %). Multivariate analysis showed age ≥15 years old at diagnosis was associated with both poor survival rate and high TRD. Adolescents with AML had inferior survival due to a higher incidence of TRD, especially after failure of initial frontline treatment.
-
Moritake H., Obara M., Sameshima N., Asada Y., Komatsu H., Hyakuna N., Sugita K., Ishida Y., Kato M., Tanizawa A., Deguchi T., Imamura T., Kitanaka A., Shimoda K., Kamimura S., Nunoi H.
International Journal of Hematology 102 ( 3 ) 349 - 356 2015年9月
担当区分：筆頭著者 記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：International Journal of Hematology
© 2015, The Japanese Society of Hematology. Bone marrow necrosis (BMN) is a rare phenomenon in children with malignancies, occurring most commonly in patients with acute lymphoblastic leukemia (ALL). The pathophysiology of this phenomenon has not been identified. We analyzed seven BMN cases with ALL in order to elucidate the underlying mechanism. Serum high-mobility group box 1 (HMGB1), cytochrome C, cytokines, and chemokines were measured, and real-time quantitative reverse transcription-polymerase chain reaction (RQ-RT-PCR) and immunochemistry of death-related molecules were analyzed using bone marrow samples. The serum levels of 17 of 27 cytokines and chemokines were found to be significantly elevated in patients with BMN in comparison to those in healthy volunteers; however, IFN-γ and IL-10 were not elevated. The cytokine pattern was different to that reported in hemophagocytic lymphohistiocytosis. The HMGB1 and cytochrome C levels in patients with BMN were not elevated. RQ-RT-PCR revealed significant overexpression of Fas-ligand, perforin, and granzyme B in the bone marrow of patients with ALL complicated with BMN compared with that in healthy volunteers and in patients with ALL without BMN. On immunohistochemistry, we identified leukemic cell-eliciting Fas-ligand and macrophage-eliciting TNF-α. Thus, no close relationship with massive necrosis or the intrinsic pathway of apoptosis was identified in the occurrence of BMN. These results suggest that the massive cell death phenomenon called BMN is partially induced by the extrinsic pathway of apoptosis.
-
Psychosocial difficulties in adolescent and young adult survivors of childhood cancer 査読あり
Takei Y., Ogata A., Ozawa M., Moritake H., Hirai K., Manabe A., Suzuki S.
Pediatrics International 57 ( 2 ) 239 - 246 2015年4月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Pediatrics International
© 2014 Japan Pediatric Society. Background With a large number of children surviving cancer worldwide, numerous investigations have assessed psychological and social adjustment among childhood cancer survivors. According to these studies, it is unclear whether childhood cancer survivors successfully adjust to daily life after being discharged from hospital, especially for adolescent and young adult survivors who have unique needs and concerns. The primary aim of this study was to identify the factors underlying psychosocial difficulties faced by adolescent and young adult survivors in their day-to-day lives after being discharged from hospital. Methods Semi-structured interviews were conducted. Twenty-five childhood cancer survivors were recruited from two regional cancer institutions in Japan. Content analysis was applied to the responses. Results Nineteen attributes were extracted and classified into four categories as follows: physical difficulties, interpersonal difficulties, behavioral difficulties, and uncertainty about the future. The attributes indicated by > 50% of the participants were "I am worried about not feeling well," "I have difficulty continuing treatment in daily life," "I have difficulty moving my body," "I have to be absent from school or work because of illness," and "I am left behind academically." Conclusions This study identified important factors of psychosocial day-to-day difficulties. Clinically, these results suggest that it is important to watch for these signs and to provide early support to survivors so that their daily life and development are not hindered by the treatment and its side-effects, and to offer long-term support focusing on individual patient characteristics such as sex, age, and cancer history.
DOI： 10.1111/ped.12495
-
Proposed strategy for the use of high-dose chemotherapy with stem cell rescue and intrathecal topotecan without whole-brain irradiation for infantile classic medulloblastoma. 査読あり
Yamada A., Moritake H., Kamimura S., Yamashita S., Takeshima H., Nunoi H
Pediatr Blood & Cancer 2014年12月
記述言語：英語 掲載種別：研究論文（学術雑誌）